Mesoblast (ASX:MSB) has enrolled 159-patients into its clinical trial for cell therapy on end-stage heart failure patients.
The regenerative medicine company’s trial involves its novel allogeneic MPC therapy (mesenchymal precursor cell (MPC)) on heart failure patients, who need left ventricular assistant devices.
The trial is funded by the United States National Institute of Health and the Canadian Institute of Health Research.
Currently about there is about 50,000 end-stage heart failure patients in the US and there’s a 50 per cent chance (with maximum therapy) of surviving one year.
Mesoblast says its therapy should have a substantial positive impact on patients.
Shares in Mesoblast (ASX:MSB) are trading 0.36 per cent higher to $1.38.